BillionToOne
Carrie McGehee joined the BillionToOne team in August 2021. Carrie is passionate about expanding access to novel diagnostic tests and is recognized for her ability to gain coverage and contracts with Medicare, Medicaid, and private insurance companies. Her work has been defined by developing and implementing strategic and innovative ways to overcome challenges that accelerate top and bottom-line growth. Carrie brings over 20 years of experience working with molecular diagnostic companies and has held several leadership positions including 11 years at Genzyme Genetics and 6 years at Sequenom Center for Molecular Medicine, the first company to bring non-invasive prenatal testing (NIPT) to the market. Carrie and her team were instrumental in policy development for NIPT and contracted with over 200 payers in the US.
Carrie started her career in healthcare as a neonatal intensive care and pediatric Registered Nurse. She graduated from North Texas Central College with a degree in Nursing.
This person is not in any offices
BillionToOne
4 followers
BillionToOne is a precision diagnostics company with the mission to make molecular diagnostics more accurate, efficient, and accessible for all. Our patent-pending molecular counter platform is the only technology platform that can accurately count the DNA molecules to the single-count level.